Clinical Trial Update: Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 neoadjuvant trial evaluating rapamycin in invasive bladder cancer stage II patients undergoing radical cystectomy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Invasive Bladder Cancer Stage II | EARLY_Phase 1 | Status: COMPLETED